For a large company, a sudden increase in the price of steel, packaging, fuel or freight can become another line in a financial model. For a small manufacturer or retailer, the same increase can decide whether the month ends in profit or loss.

That is the uncomfortable reality facing many of India’s small businesses as input costs remain a persistent concern. Small enterprises operate between two pressures: suppliers demand higher prices, while customers often resist passing the entire increase through to retail prices. The result is a squeeze on margins, working capital and, ultimately, business confidence.

Yet India’s MSME sector has one advantage that large organisations sometimes lack: adaptability. The next phase of resilience will depend less on waiting for costs to normalise and more on how intelligently small businesses manage cash, technology and supply chains.

Margins Are Becoming a Management Problem

For a small manufacturing unit, higher input prices do not automatically translate into higher selling prices. A local furniture maker, garment manufacturer, engineering workshop or food processor may face customers who can simply move to another supplier if prices rise too sharply.

That leaves the entrepreneur with difficult choices: reduce margins, reduce production, renegotiate with suppliers or postpone expansion.

The first response should be tighter working-capital discipline. Inventory that once looked like security can become expensive when prices are volatile. Overstocking locks cash into materials that may take weeks or months to convert back into revenue.

Lean inventory management, faster receivables collection and closer monitoring of supplier payment terms can therefore become as important as sales growth. For smaller firms, cash flow is often a more immediate survival metric than the size of the order book.

Digitalisation Is No Longer Optional

India's digital payment ecosystem has already changed the way small businesses receive and make payments. The Ministry of MSME itself highlights digital transactions as an important part of the sector's formalisation and tracks digital-payment adoption among enterprises.

The next opportunity is to use that digital trail more productively.

Regular UPI receipts, GST records, bank transactions and digitally generated invoices can help create a more transparent picture of a business's cash flows. For eligible enterprises, stronger financial records can improve access to formal credit and reduce dependence on informal borrowing.

But digitalisation should not be confused with simply accepting QR-code payments. The bigger opportunity lies in connecting payments, accounting, inventory, invoicing and credit into one operating system.

For an entrepreneur facing a temporary cash-flow gap, the difference between having reliable financial records and having fragmented records can be significant.

Formal Credit Can Ease the Cash Crunch

Working-capital shortages are particularly dangerous when input prices rise. A business may have confirmed orders but still lack the money to purchase raw material, pay workers or meet transport expenses before customers make their payments.

This is where India's formal MSME credit architecture becomes important. The Ministry's current dashboard shows substantial activity under credit-guarantee and other MSME support programmes, while the government continues to promote formalisation and digital platforms for enterprise finance.

The challenge, however, is not merely making credit available. Small businesses need credit that arrives at the right time, at a sustainable cost and against realistic assessments of their cash flows.

Entrepreneurs should therefore treat formalisation as a business asset rather than merely a compliance obligation. Updated registrations, clean accounts, timely tax filings and documented transactions can strengthen the financial profile of an enterprise.

Local Suppliers Can Become a Strategic Advantage

The globalisation of supply chains delivered scale and price advantages, but recent disruptions have also exposed their vulnerabilities.

For smaller Indian businesses, the answer does not necessarily mean abandoning national or international suppliers. It means identifying where a shorter and more diversified supply chain makes economic sense.

A manufacturer that can source certain components from a supplier within its state may save not only on freight but also on delivery time, minimum-order constraints and emergency procurement costs. A retailer may benefit from developing relationships with regional wholesalers rather than depending entirely on distant distributors.

This is not a retreat from globalisation. It is supply-chain diversification at the local level.

NITI Aayog has identified transportation, inventory and supply-chain design as important components of India's logistics-cost challenge. Its freight-efficiency analysis has also pointed to the potential for reducing costs through better transport and inventory management.

For MSMEs, those national-level efficiencies translate into very practical questions: How far does a raw material travel? How many times is it handled? How much stock must be maintained because delivery is unreliable?

Technology Must Improve Productivity, Not Just Visibility

There is a tendency to describe digital adoption as an automatic solution for small businesses. It is not.

Buying software without changing business processes does little. The real gains come when technology helps an entrepreneur identify slow-moving inventory, predict demand, compare supplier prices, track receivables or reduce paperwork.

The government's MSME ecosystem increasingly includes initiatives around technology, quality, digitalisation and market access. The current MSME dashboard, for example, tracks programmes including RAMP, ZED and LEAN, alongside credit and formalisation indicators.

The opportunity for entrepreneurs is to choose technology according to a specific business problem rather than adopting it simply because it is fashionable.

Resilience Will Be Built Locally

India's MSMEs cannot control commodity prices, global freight rates or geopolitical disruptions. They can, however, control how much cash remains tied up in inventory, how quickly invoices are collected, how dependent they are on a single supplier and how visible their financial performance is to lenders.

That is where resilience begins.

The policy conversation around MSMEs often focuses on subsidies, schemes and credit. Those tools matter, but long-term competitiveness will also depend on operational discipline inside individual businesses.

A small enterprise that maintains lean inventory, builds multiple supplier relationships, uses digital records, understands its cash conversion cycle and accesses formal finance when necessary is better positioned to absorb an input-cost shock.

India's small businesses have survived repeated disruptions because they are accustomed to adapting. The next challenge is to turn that instinctive resilience into a more systematic advantage.

The future of India's MSME sector may not be defined by whether input costs fall quickly. It may be defined by whether small businesses become efficient enough to remain profitable even when costs do not.

India imports about 65% of the raw materials needed to make medicines from China, NITI Aayog said Tuesday, warning that heavy dependence on a single country or region leaves the pharmaceutical supply chain vulnerable.

Speaking while releasing the Trade Watch quarterly report, NITI Aayog Vice‑Chairperson Ashok Kumar Lahiri said the “Middle East crisis” has underlined the need to diversify suppliers for critical inputs such as medicines, oil and gas. “We should not depend on one country or region,” he told reporters, adding that India must ensure multiple sources for energy and other essential supplies so crises do not disrupt domestic availability.

The report — which also presents data on India’s overall imports‑exports and energy sector — found that while India is a global leader in producing affordable generic drugs, much of the active pharmaceutical ingredients (APIs) and other chemical inputs still come from China. Officials said the finding supports recent policy discussions on securing supply chains and boosting domestic capability.

Lahiri urged negotiators to include a dedicated pharmaceuticals chapter in any free trade agreement (FTA). “When negotiating FTAs with countries or blocs, a separate chapter on pharmaceutical products should be included,” he said, according to excerpts shared by the Aayog. The recommendation reflects concerns that tariff and non‑tariff provisions must specifically protect and promote India’s pharma value chain.

The report also highlighted rising costs for R&D and manufacturing in India. Stricter environmental rules, Lahiri noted, have pushed up the cost of running production facilities and carrying out research into new drugs. “Environmental regulations have become quite tight. That has increased the cost for companies to produce medicines and pursue new R&D,” he said. The Aayog suggested that India’s system for translating academic research into commercial products needs strengthening to attract long‑term investors.

India’s strength remains production. The Aayog’s study concluded that India performs well on drug manufacturing but needs to move up the value chain — into higher‑margin, branded and innovative products — to capture greater global value. “Indian firms have good international credibility. If they bring high‑quality, reasonably priced branded products, our grip on global markets can strengthen,” Lahiri said.

The report also underlined India’s role as a supplier of affordable generics worldwide: about half of the low‑cost medicines exported from India go to African countries. In 2025, global demand for medicines and inputs was estimated at roughly ₹123.13 lakh crore (about $1.3 trillion), of which about ₹96.61 lakh crore went to finished medicines and roughly ₹24.72 lakh crore to chemicals and raw materials used by drug makers, the Aayog noted.

To reduce dependence on imports and build resilience, the Aayog offered a set of policy suggestions:

• Encourage Indian firms to move beyond generics into high‑value pharmaceutical segments.

• Strengthen links from college and university research to industry so discoveries commercialise faster.

• Make regulatory approvals for life‑sciences innovation clearer, faster and more transparent to draw patient long‑term investment.

• Include pharma‑specific provisions in FTAs and pursue bilateral deals — Lahiri said India and the US are close to finalising a bilateral trade pact and expected to sign it soon.

Experts and industry sources say the challenge is not only policy but capacity and investment. Building API manufacturing at scale requires capital, land, and trained personnel; cleaning up chemical manufacturing to meet environmental norms adds to costs. The Aayog’s recommendations aim to balance ecological compliance with incentives for domestic production.

Further details on timelines, funding packages or specific incentives were not available in the report. Authorities are reviewing follow‑up measures, and officials said more clarity on implementation will be provided as the government consults industry stakeholders.

Why it matters
India’s dependence on China for pharma inputs is a strategic vulnerability for public health and industrial policy. Any disruption — from geopolitical tensions to supply shocks — can affect drug availability and prices at home and for countries that rely on Indian exports. Moving up the value chain would also help India capture higher margins and reduce exposure to external suppliers.

Further details are awaited as policymakers and industry leaders discuss the Aayog’s recommendations and the implications for upcoming trade talks.